Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company developing drugs to treat rare cardiopulmonary diseases. Pulmonary Arterial Hypertension is a rare progressive and often fatal cardiopulmonary disease affecting both the heart and lungs. Aerovate's lead program, AV-101, is an inhalable dry to address the underlying hyperproliferation of cells within the narrowed arteries of the lungs. Aerovate Therapeutics was incorporated in 2018 and is headquartered in Waltham, MA.